©2019 by APAC Biotech

IMG_8229_edited.jpg

Frontiers In The Development Of Personalised Therapies

Apac Biotech was built on the belief that our immune system is powerful enough to fight cancer from within and now with Apac’s personalised immunotherapies we plan turn the tables on cancer and fight with the cancer patients. 
Our flagship product APCEDEN® was the first Indian FDA approved immunotherapy product for the treatment of cancer. Today, our versatile research team of scientists and doctors are going deeper into creating unmatched personalised therapeutics to enhance the immune system further

 

OUR PROMISE

Our commitment to improve the quality of life of our cancer patients,
their families, drives us in everything we do and 
we never give up.

 

Dedication

  • Dedicated to our patients by enhancing their immune system through APCEDEN® (Dendritic cell personalised immunotherapy product) to fight cancer.

  • Enhancing the patient’s immune system by using the patient’s own immune cells ensuring a well tolerated safety profile

The Future

  • Make APCEDEN® personalised immunotherapy available to patient’s in India and around the world

  • Enhancing the technology further to explore the uses of personalised immunotherapy in other cancer treatments.

Milestones Achieved

2009

Pre-Clinical Studies for monocyte derived dendritic cells & validation of it's therapeutic value in cancer patients

2011

Trial registration done. 1st Patient enrolled in Phase 2 study

2012

Completion of Trial and Data Analysis of the results concluded

2013 (February)

APAC Biotech's research is reviewed by a Scientific Review Board (SRB) consisting of independent experts and scientists

2013 (May)

APAC Biotech Presents the trial data before the CBBTDEC (Cell Biology Based Therapeutic Drug Evaluation Committee)

2013 (December)

APAC Biotech files an application for Market Authorisation for APCEDEN® as per the letter from the Drug Controller General Of India (DCGI)

2014

Facility Inspection conducted by the CDSCO and ICMR (Indian Council Of Medical Research)

2017 (March)

APAC Biotech becomes the first Indian Biotechnology company to receive the post marketing study (PMS) for it's personalised dendritic cell based immunotherapy, APCEDEN®, by the Indian FDA

2017 (September)

Received NOC from the DCGI for APCEDEN® protocol

2018

Commenced signing agreements with various hospitals for marketing of APCEDEN®

 

Team

Get to Know Us

Arun Mehra

Managing Director / CEO

Dr. Bandana Sharan

Research Director

Chaitanya Kumar

Associate Research Director

Dr. Jasmine Bagga

Application Scientist